Dougherty & Co Starts Sequenom (SQNM) at Buy; See MaterniT21 Becoming the New Gold Standard of Care in Down Syndrome Testing
Tweet
Share
E-mailGet Alerts SQNM Hot Sheet
Price: $2.39 --0%
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
3 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Dougherty & Co initiates coverage on Sequenom (NASDAQ: SQNM) with a Buy. PT $7.00.
Dougherty analyst said, "We’re excited about Sequenom’s recently launched MaterniT21, a non-invasive molecular diagnostic test for Down syndrome (Trisomy 21). Pivotal clinical trial results demonstrated robust diagnostic performance, with high sensitivity (~99.1%) and very low false positive rates...We are excited about the potential for MaterniT21 to become the new gold standard of care for Down syndrome screening and diagnosis."
"We expect share price performance to be driven by: 1) Positive payer/reimbursement decisions in 1H:12. 2) Hospital/facility decisions to incorporate MaterniT21 testing as part of diagnostic services. 3) Overall solid launch execution (i.e., sales/marketing traction, CLIA lab expansion, physician receptivity, etc.)."
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.28 yesterday.
Dougherty analyst said, "We’re excited about Sequenom’s recently launched MaterniT21, a non-invasive molecular diagnostic test for Down syndrome (Trisomy 21). Pivotal clinical trial results demonstrated robust diagnostic performance, with high sensitivity (~99.1%) and very low false positive rates...We are excited about the potential for MaterniT21 to become the new gold standard of care for Down syndrome screening and diagnosis."
"We expect share price performance to be driven by: 1) Positive payer/reimbursement decisions in 1H:12. 2) Hospital/facility decisions to incorporate MaterniT21 testing as part of diagnostic services. 3) Overall solid launch execution (i.e., sales/marketing traction, CLIA lab expansion, physician receptivity, etc.)."
For an analyst ratings summary and ratings history on Sequenom click here. For more ratings news on Sequenom click here.
Shares of Sequenom closed at $4.28 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Resumes Oberoi Realty Ltd (OBER:IN) at Buy (1)
- BMO Capital Resumes Snowline Gold Corp (SGD:CN) (SNWGF) at Outperform
- RBC Capital Starts Krystal Biotech (KRYS) at Outperform
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
